Evidence map›Paper›PMID 35852878›Full record

ArticleAging2022

Metformin and breast cancer: an opportunity for pharmacogenetics.

Elisabet Cuyàs, Begoña Martin-Castillo, Javier A Menendez

Full text readEditorial
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elisabet CuyàsMetabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology-Girona Biomedical Research Institute, Girona, Spain.
Begoña Martin-CastilloClinical Research Unit, Catalan Institute of Oncology-Girona, Girona, Spain.
Javier A MenendezMetabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology-Girona Biomedical Research Institute, Girona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsDiabetes Mellitus, Type 2MetforminErb-b2 Receptor Tyrosine KinasesFemaleHumansHypoglycemic AgentsPharmacogeneticsErb-b2 Receptor Tyrosine KinasesHypoglycemic AgentsMetforminbreast cancerHER2metforminsingle-nucleotide varianttype 2 diabetes

Identifiers

PMID35852878
PMCPMC9365564

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.